Pyrgidis Nikolaos, Moschini Marco, Tzelves Lazaros, Somani Bhaskar K, Juliebø-Jones Patrick, Del Giudice Francesco, Mertens Laura S, Pichler Renate, Volz Yannic, Ebner Benedikt, Eismann Lennert, Semmler Marie, Pradere Benjamin, Soria Francesco, Stief Christian G, Schulz Gerald B
Department of Urology, University Hospital, Ludwig Maximilian University Munich, 81377 Munich, Germany.
Department of Urology, Urological Research Institute, San Raffaele Scientific Institute, 20132 Milan, Italy.
J Clin Med. 2024 Jun 17;13(12):3531. doi: 10.3390/jcm13123531.
Photodynamic diagnosis (PDD) during transurethral resection of bladder tumor (TURBT) is guideline recommended, as it improves bladder cancer detection rates. However, the extent to which PDD is implemented in everyday clinical practice has not been thoroughly assessed. We aimed to evaluate the current trends and major perioperative outcomes of TURBT with PDD. The present study evaluated the GeRmAn Nationwide inpatient Data (GRAND) from 2010 (the year when PDD started to be coded separately in Germany) to 2021, which were made available from the Research Data Center of the German Bureau of Statistics. We undertook numerous patient-level and multivariable logistic regression analyses. Overall, 972,208 TURBTs [228,207 (23%) with PDD and 744,001 (77%) with white light] were performed. Patients offered PDD during TURBT were younger ( < 0.001), presented fewer comorbidities ( < 0.001) and were discharged earlier from hospital ( < 0.001). PDD was associated with additional costs of about EUR 500 compared to white-light TURBT ( < 0.001). The yearly TURBT cases remained relatively stable from 2010 to 2021, whereas utilization of PDD underwent a 2-fold increase. After adjusting for major risk factors in the multivariate regression analysis, PDD was related to lower rates of transfusion (1.4% vs. 5.6%, OR: 0.29, 95% CI: 0.28 to 0.31, < 0.001), intensive care unit admission (0.7% vs. 1.4%, OR: 0.56, 95% CI: 0.53 to 0.59, < 0.001) and 30-day in-hospital mortality (0.1% vs. 0.7%, OR: 0.24, 95% CI: 0.22 to 0.27, < 0.001) compared to white-light TURBT. On the contrary, PDD was related to clinically insignificant higher rates of bladder perforation (0.6% versus 0.5%, OR: 1.3, 95% CI: 1.2 to 1.4, < 0.001), and reoperation (2.6% versus 2.3%, OR: 1.2, 95% CI: 1.1 to 1.2, < 0.001). The utilization of PDD with TURBT is steadily increasing. Nevertheless, the road toward the establishment of PDD as the standard of care for TURBT is still long, despite of the advantages of PDD.
在经尿道膀胱肿瘤切除术(TURBT)期间进行光动力诊断(PDD)是指南推荐的做法,因为它能提高膀胱癌的检出率。然而,PDD在日常临床实践中的实施程度尚未得到全面评估。我们旨在评估采用PDD的TURBT的当前趋势和主要围手术期结果。本研究评估了2010年(PDD在德国开始单独编码的年份)至2021年的德国全国住院患者数据(GRAND),这些数据由德国统计局研究数据中心提供。我们进行了大量患者层面的多变量逻辑回归分析。总体而言,共进行了972,208例TURBT[228,207例(23%)采用PDD,744,001例(77%)采用白光]。在TURBT期间接受PDD的患者更年轻(<0.001),合并症更少(<0.001),且出院更早(<0.001)。与白光TURBT相比,PDD相关的额外费用约为500欧元(<0.001)。从2010年到2021年,每年的TURBT病例数相对稳定,而PDD的使用率增长了两倍。在多变量回归分析中调整主要危险因素后,与白光TURBT相比,PDD与较低的输血率(1.4%对5.6%,OR:0.29,95%CI:0.28至0.31,<0.001)、重症监护病房入院率(0.7%对1.4%,OR:0.56,95%CI:0.53至0.59,<0.001)和30天住院死亡率(0.1%对0.7%,OR:0.24,95%CI:0.22至0.27,<0.001)相关。相反,PDD与临床上无显著意义的较高膀胱穿孔率(0.6%对0.5%,OR:1.3,95%CI:1.2至1.4,<0.001)和再次手术率(2.6%对2.3%,OR:1.2,95%CI:1.1至1.2,<0.001)相关。TURBT中PDD的使用率正在稳步上升。然而,尽管PDD有诸多优势,但将其确立为TURBT护理标准的道路仍很长。